{'fraction_non_alphanumeric': 0.03189066059225513, 'fraction_numerical': 0.015945330296127564, 'mean_word_length': 4.8061674008810575, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Preparation and identification of monoclonal antibodies to estrogen and progesterone receptors].

OBJECTIVE
Preparation of anti human progesterone receptor (PR) and estrogen receptor (ER) monoclonal antibodies (McAb).


METHODS
Characterization of the two McAbs were detected by Western blot, immunohistochemical, immunofluorescence and fluocytometer techniques.


RESULTS
(1) A specific protein belt was obtained between anti-PR McAb and the extract of cell line T47D and the same result was noticed between anti-ER McAb and extract from MCF-7 cell line by Western blot. (2) The PR and ER status of 40 and 35 human breast cancer were studied by immunohistochemistry (IHC) using the anti-PR and ER McAb. The efficacy of the McAbs prepared was just the same as that of the McAbs purchased from Zymed company. The corresponding rate of determination for ER and PR status between IHC and DCC were 85% and 91.4%, respectively. (3) The fluorescent markers were mainly localized in the cell nuclei when detected through indirect immunofluorescence techniques. (4)FCM showed that fluorescent index was larger than 1.0, and negative control F1 was less than 1.0.


CONCLUSION
The anti-PR and ER McAbs prepared in this program are specific and sensitive and have the similar efficacy and quality as the Zymed PR and ER McAbs.